RIKEN VITAMIN CO.,LTD.

理研ビタミン

Industry: Foods
Market: Prime
Accounting standards: Japanese GAAP
Consolidation basis: Consolidated

Notes

Stock adjustments
Apr 1, 2020 Stock split 1 share → 2 shares

Key metrics

Revenue(million JPY)

Mar 2021

77,722

Mar 2022

79,231

Mar 2023

88,750

Mar 2024

91,484

Mar 2025

95,582

Operating profit(million JPY)

Mar 2021

1,367

Mar 2022

5,840

Mar 2023

7,158

Mar 2024

9,371

Mar 2025

8,724

Operating profit margin(%)

Mar 2021

1.76

Mar 2022

7.37

Mar 2023

8.07

Mar 2024

10.24

Mar 2025

9.13

Profit before tax(million JPY)

Mar 2021

-7

Mar 2022

20,313

Mar 2023

7,857

Mar 2024

11,909

Mar 2025

12,706

Profit(million JPY)

Mar 2021

-1,618

Mar 2022

21,582

Mar 2023

6,414

Mar 2024

8,755

Mar 2025

9,388

Total assets(million JPY)

Mar 2021

106,535

Mar 2022

102,660

Mar 2023

105,223

Mar 2024

118,776

Mar 2025

112,999

Cash and cash equivalents(million JPY)

Mar 2021

18,655

Mar 2022

15,064

Mar 2023

16,656

Mar 2024

20,141

Mar 2025

18,835

Cash flows from operating activities(million JPY)

Mar 2021

7,625

Mar 2022

6,823

Mar 2023

7,835

Mar 2024

10,451

Mar 2025

7,892

Cash flows from investing activities(million JPY)

Mar 2021

-2,288

Mar 2022

-3,661

Mar 2023

-2,034

Mar 2024

-554

Mar 2025

353

Cash flows from financing activities(million JPY)

Mar 2021

-180

Mar 2022

-7,565

Mar 2023

-4,578

Mar 2024

-7,084

Mar 2025

-9,965

Return on equity(%)

Mar 2021

Mar 2022

38.3

Mar 2023

9.3

Mar 2024

11.8

Mar 2025

12.1

Equity ratio(%)

Mar 2021

43.3

Mar 2022

64.8

Mar 2023

67.8

Mar 2024

64.5

Mar 2025

70.1

Earnings per share(JPY per share)

Mar 2021

-49.36

Mar 2022

657.98

Mar 2023

195.51

Mar 2024

268.44

Mar 2025

310.08

Net assets per share(JPY per share)

Mar 2021

1,407.47

Mar 2022

2,027.84

Mar 2023

2,174.39

Mar 2024

2,523.84

Mar 2025

2,649.95

Dividend per share(JPY per share)

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Payout ratio(%)

Mar 2021

Mar 2022

6.99

Mar 2023

30.18

Mar 2024

30.17

Mar 2025

30.31

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.